Amyris, Inc. (NASDAQ:AMRS)‘s stock had its “buy” rating reiterated by equities researchers at Rodman & Renshaw in a research report issued to clients and investors on Wednesday. They currently have a $4.00 price objective on the stock. Rodman & Renshaw’s target price suggests a potential upside of 398.13% from the company’s current price.
Several other analysts have also weighed in on the stock. Singular Research reiterated a “buy” rating and issued a $2.80 price objective on shares of Amyris in a research note on Wednesday, September 28th. Zacks Investment Research lowered shares of Amyris from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $2.66.
Amyris (NASDAQ:AMRS) traded down 1.62% on Wednesday, hitting $0.79. 737,717 shares of the stock traded hands. Amyris has a 1-year low of $0.31 and a 1-year high of $1.63. The stock has a 50-day moving average price of $0.78 and a 200 day moving average price of $0.61. The company’s market cap is $207.78 million.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.01. The business had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $33.61 million. During the same period last year, the firm posted ($0.23) EPS. The business’s revenue was up 208.1% on a year-over-year basis. On average, analysts anticipate that Amyris will post ($0.25) EPS for the current fiscal year.
In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of Amyris stock in a transaction on Friday, November 4th. The shares were sold at an average price of $0.89, for a total value of $2,323,997.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 48.70% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Amyris stock. KBC Group NV raised its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 330.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 329,101 shares of the company’s stock after buying an additional 252,589 shares during the period. KBC Group NV owned about 0.14% of Amyris worth $191,000 as of its most recent filing with the SEC. 30.44% of the stock is currently owned by hedge funds and other institutional investors.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.